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0.05) on the SF 12. Properly monitored patients spent signiﬁ cantly more on total 
health care services (+$5243), outpatient visits (+$1023), and medications (+$1204), 
respectively (all P-values<0.05). CONCLUSIONS: In the US, nearly 40% patients with 
diabetes do not receive the proper diabetes monitoring controlling for racial and 
socioeconomic disparities. Anti-diabetics/insulin use, mental/cognitive status, physical 
health status, and health care expenditure may also interact with performing monitor-
ing. Barriers and cost-beneﬁ t for long-term monitoring should be studied.
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IMPROVING PATIENT CARE: RESULTS FROM THE TEXAS NEWBORN 
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BACKGROUND: Advances in screening technology have led to rapid expansion of 
newborn screening as a public health initiative in the United States. Due to variation 
across states in program implementation, there is a lack of standardization and 
accountability, which can affect quality of care. Texas currently screens for 28 disor-
ders. OBJECTIVES: The Texas Newborn Screening Performance Measures Project 
was initiated with the objective of developing evidence-based performance measures 
to improve quality, accountability and uniformity in the care. METHODS: A three 
step approach was used for identiﬁ cation and development of key measures for seven most 
critical disorders: systematic reviews; impact assessment; and feasibility assessment. Impact 
assessments (likert scale) were based on National Quality Measures Clearinghouse™ 
(NQMC) criteria: scientiﬁ c soundness, relevance, health importance, impact on quality of 
care, and ability to address disparities in care. A likert scale was also used for feasibility 
assessment on key aspects: data availability, ease of collection, infrastructure and human 
resource needs, overall cost, and time constraints. RESULTS: A total of 50 performance 
measures were supported by scientiﬁ c evidence. Impact and feasibility assessments led 
to the approval of 33/50 measures. “Time to initiate treatment” received the highest 
scores on potential impact on patient outcomes (mean impact score 86.67/100, SD 
1.5). Other measures with potentially high impact (score >80/100) were: compliance 
with oral prophylactic medication and age at ﬁ rst Prevnar® vaccination in sickle cell 
disease; screening of at-risk family members in fatty acid disorders; frequency of 
growth assessments in congenital adrenal hyperplasia and phenylalanine levels in 
phenylketonuria. “Time to treatment” for individual disorders was also ranked very 
high on feasibility (mean feasibility score 88.67/100, SD 3.88). CONCLUSIONS: This 
is one of the ﬁ rst efforts to identify and develop evidence-based performance measures 
in newborn screening and can pave the way for system wide changes and development 
of national guidelines.
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OBJECTIVES: Investigate the type 2 diabetes mellitus (T2DM) treatment practice and 
achievement of therapeutic goals in a cohort of T2DM patients treated in the Brazilian 
PHCS. METHODS: This is a cross-sectional analysis of 383 T2DM outpatients 
treated in 5 cities covered by the PHCS. Data was collected using information from 
the previous year by interviewing patients using a validated questionnaire comple-
mented by medical chart review. Therapeutic goals suggested by the Brazilian Diabetes 
Society were used as standard treatment. RESULTS: Mean age was 60.5 ± 9.6 years, 
mean BMI 29.1 ± 5.3 Kg/m2 and mean duration of diabetes of 12.2 ± 8.75 years. The 
frequency of associated arterial hypertension was 66.8% (n = 256); obesity 39% n = 
144); dyslipidemia 69.6% (n = 267) and heart failure 5.5% (n = 21). Microvascular 
complications were present in 32.4% (n = 124); 8.1% (n = 31) had macrovascular 
complications; 18% (n = 69) had at least one micro and one macrovascular complica-
tion and 41.5% (n = 159) had no complications. Current treatment practice was: 3.6% 
(n = 14) diet only; 30% (n = 115) monotherapy with oral anti-diabetic (OAD); 37.8% 
(n = 145) combined therapy with more than one OAD agents; 23.2% (n = 89) com-
bined therapy with insulin and 5.2% (n = 20) just insulin. The most prescribed drug 
was metformin (41.4%), followed by insulin (19.1%), sulphonylureas (18.6%), DPP4 
inhibitors (8.7%), TZDs (5.5%), and others (6.7%). Medications for dyslipidemia 
was used by 47.5% (n = 178); cardiovascular drugs in 77.4% (n = 287) and anti-
obesity drugs in 4% (n = 15). Treatment targets were achieved in: 76.8% for systolic 
and diastolic blood pressure (<130 × 85 mmHg), 19.5% for BMI < 25 kg/m2, 28% 
for HDL cholesterol >55 women, 37.3% for HDL cholesterol >45 men and 28.2% 
reached the goal for HbA1c (within normal range). Only 6.8% of the group (n = 26) 
reached all the treatment targets. CONCLUSIONS: The national goals for glycemic 
control, blood pressure and lipid levels are rarely achieved in real-world clinical 
practice, even with the high use of medications. 
DIABETES/ENDOCRINE DISORDERS – Conceptual Papers & Research on 
Methods
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OBJECTIVES: Diabetes mellitus type 2 (T2DM) is a chronically progressive disease 
and the treatment must be selected according to the pathophysiological phase of the 
disease at the time the treatment is begun. The Croatian public diabetology sector 
takes care of approximately 150,000 adults treated with oral hypoglycemic agents 
(OHA) alone or in combination with insulin. Our objective was assessment of the 
clinical and economic consequences of OHA treatment in T2DM from a Croatian 
health care system perspective. METHODS: The target population deﬁ ned for the 
study was diabetic patients treated with OHA alone. Medication consumption was 
quantiﬁ ed by using Pharmis and CroDiab data. a clinical expert panel provided 
resource-use information not available in published literature or health care databases. 
RESULTS: Current consumption data is showing that 62.8% patients are using OHA 
as monotherapy. Within this group, majority is using either biguanides or sulphonyl-
ureas. Patients treated with sulphonylureas are represented with almost the same 
percentage as those treated with biguanides (25% vs. 29%). Combination of two 
OHA is used in 34.2% while 3% of patients are treated by triple therapy. The most 
often choice in dual therapy is combination of biguanides and sulphonylureas while 
biguanides, sulphonylureas and thiazolidinediones in combination as the most favour-
able treatment option in triple therapy. Biguanides are used as a one of OHA in 61% 
of patients. CONCLUSIONS: Considering current clinical guidelines, lifetime beneﬁ ts 
of biguanides and facts that they are low-cost agent, relatively small proportion of 
T2DM patients are treated with this agent in Croatia. Findings of this investigation 
revealed real life pattern of T2DM treatment, which enables directing in better treating 
and more cost-effective management in Croatia.
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OBJECTIVES: Using a large, US administrative pharmacy claims database, calculate 
proportion of days covered (PDC) using actual days supply, and compare estimated 
PDC (ePDC) using days supply derived from drug-speciﬁ c Deﬁ ned Daily Dose (DDD) 
criteria. METHODS: Continuously eligible patients ﬁ lling non-insulin anti-diabetic 
medication were targeted from a large sample of pharmacy claims during 2008 and 
2009. Medications were grouped into ATC diabetes drug classes. Proportion of days 
covered (PDC) was calculated as the number of days a patient had medication in their 
possession divided by the number of days in the period. PDC was ﬁ rst calculated using 
actual days supply, then ePDC was calculated using an estimated days supply from 
DDD, strength, and pill quantity. The percent of patients adherent to therapy was 
deﬁ ned by a PDC > 0.80. The reliability of each method was assessed by Pearson 
correlation coefﬁ cients and agreement above chance was assessed using Kappa statis-
tics. RESULTS: Adherence was calculated for 163,750 patients taking non-insulin 
anti-diabetics. Overall, the PDC was 0.69 and ePDC 0.57. The two measures were 
also highly and signiﬁ cantly correlated (r = 0.73; P < 0.0001). The percent adherent 
was 48.8% (PDC) and 34.4% (ePDC), (Kappa = 0.50; P < 0.0001). At the medication 
class level, differences in PDC and ePDC ranged from 0.01 to 0.35, with correlation 
coefﬁ cients ranging from 0.40 to 0.93. Differences in the percent adherent metric 
ranged from −2.3 to 23.2, and kappa values from 0.22 to 0.89. CONCLUSIONS: 
Applying DDD estimates for the purposes of diabetes adherence estimation when 
lacking days supply values may provide reasonable estimates of adherence based on 
results presented here. At the medication class level there is greater variability in the 
reliability measures. Including claims from the U.S. only is a limitation of this analysis, 
as local treatment patterns may vary, and DDD values were not available for all U.S. 
medications.
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OBJECTIVES: Markov and Monte-Carlo (MC) models are often used to simulate 
Diabetes Mellitus (DM) and its complications over time, but reasons to choose the 
model type are poorly documented. a systematic literature review was performed to 
identify factors inﬂ uencing the choice of the model type. METHODS: Models simulat-
ing the progression of DM and its complications were selected from Medline and 
Embase databases. Literature reviews, methodological articles and non original models 
were excluded. Each full-paper selected went through a 31-item checklist via a double-
reading process. a qualitative analysis was performed to evaluate the accuracy of the 
model with the study question. RESULTS: Sixty-one models were selected, including 
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42 Markov and 19 MC. Median time since publication was 6 years. Most models 
concerned Type 2 DM (57%) and prevention or disease-management programs 
(54%). In average, models had 11 states and 2.8 complications. MC were signiﬁ cantly 
more used than Markov when both type 1 and 2 DM and a prevention or disease 
management program were concerned. Models had, signiﬁ cantly, a higher number of 
states and complications. The choice of the model type was shown to be inﬂ uenced 
by the number of DM and of complications considered. The justiﬁ cation to perform 
a Monte-Carlo was more often documented than those to perform a Markov (74% 
vs. 38%). The model was considered accurate with the study question in respectively 
86% of Monte-Carlo and 64% of Markov. CONCLUSIONS: This study allowed to 
statistically identify factors inﬂ uencing the type of model used to simulate DM. It is 
an interesting tool for modelers in their decision process to build a model. Information 
such as data and time availability or ﬁ nancial context could not be collected.
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MODEL FOR SCENARIO ANALYSIS
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OBJECTIVES: In the last 15 years, models built to appraise health technologies have 
grown in complexity to accurately reﬂ ect the natural history of disease and calculate 
costs and beneﬁ ts accordingly. The advantage of using patient level simulation models 
(PSM) over cohort models (CM) is that CM may become unwieldy with thousands 
of branches. This usually happens if the patient characteristics inﬂ uence the risks of 
complications and these vary over time, or if there are many comorbidities to take 
into account and the risk of each complication is time dependent. In this case, a typical 
Markov cohort may be unsuitable. However a PSM can take a long time to run in 
order to produce results. Aim of this research is to present a case study where a PSM 
is simpliﬁ ed with a Markov structure and to compare the results of the two models. 
METHODS: We describe how a PSM for diabetes may be adapted to a CM, stating 
all the limitations. RESULTS: Provided that the PSM gives similar answers to the CM, 
the CM may be used as a surrogate for conducting complex sensitivity analysis (e.g., 
3-way analysis or tornado diagrams). The advantage is that this model would produce 
results “instantaneously.” CONCLUSIONS: The adaptation of a PSM model to a 
cohort model may be a desirable feature if the model is required by a non technical 
audience. This is the case for “due diligence” models that are increasingly required by 
investors to assess the value of assets that a pharmaceutical company considers to buy 
or sell. Further research is needed to have a powerful test to assess whether the dif-
ference in results between a simpliﬁ ed CM model and the PSM are statistically 
signiﬁ cant. 
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OBJECTIVES: While the comorbidity burden of gout in the US has been considered 
substantial and may have been rising over the past decade, no contemporary national 
data are available. We estimated the prevalence of major comorbidities in patients 
with gout compared with those without gout based on a recent, nationally representa-
tive sample of US men and women (National Health and Nutrition Examination 
Survey [NHANES] 2007–2008). METHODS: Using data from 5707 participants in 
NHANES 2007–2008 (2797 men and 2910 women) aged 20 years and older, we 
determined the prevalence of major comorbidities among individuals with gout, 
including hypertension, renal impairment, nephrolithiasis, diabetes, myocardial infarc-
tion, heart failure, stroke, and obesity. We also compared the prevalence with those 
without gout using age- and sex-adjusted logistic regressions. Case deﬁ nitions of 
comorbidities were based on an afﬁ rmative answer to a question asking if a physician 
or a health professional had diagnosed the corresponding condition. RESULTS: 
Among US adults with gout, 74% had hypertension, 53% obesity, 26% diabetes, 24% 
nephrolithiasis, 14% myocardial infarction, 11% heart failure, 10% stroke, and 9% 
renal impairment (Table). Prevalence of these comorbidities among individuals with 
gout was substantially higher than among individuals without gout. Age- and sex-
adjusted odds ratios (95% conﬁ dence interval [CI]) were 4.19 (2.75–6.39) for hyper-
tension, 2.35 (1–55–3.57) for obesity, 2.36 (1.49–3.73) for diabetes, 2.10 (1.39–3.18) 
for nephrolithiasis, 2.37 (1.54–3.65) for myocardial infarction, 2.68 (1.88–3.83) for 
heart failure, 2.02 (0.98 to 4.19) for stroke, and 3.50 (2.05–5.98) for renal impair-
ment. CONCLUSIONS: These ﬁ ndings from the latest nationally representative 
sample of US adults in NHANES 2007–2008 conﬁ rm that the prevalence of comor-
bidities among individuals with gout is substantial and considerably higher than 
among individuals without gout.
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DISABILITY OUTCOMES AND DOSE ESCALATION IN RHEUMATOID 
ARTHRITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR 
BLOCKERS: A COMPARATIVE EFFECTIVENESS ANALYSIS
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OBJECTIVES: Previous cohort studies using US commercial insurance claims of 
rheumatoid arthritis (RA) patients have observed higher dose escalation rates for 
patients treated with tumor necrosis factor-α (TNF) blockers inﬂ iximab (INF) or 
adalimumab (ADA) than for etanercept (ETN). However, such databases cannot be 
used to determine whether dose escalation is associated with improved clinical out-
comes. We compared functional disability and dosing history between patients treated 
with TNF blockers using data from a large, prospective observational registry (Arthri-
tis, Rheumatism, and Aging Medical Information System; ARAMIS) of RA patients 
in the US. METHODS: ARAMIS enrolled adult physician-diagnosed RA patients. 
Patients who met following inclusion criteria were selected: treated with a TNF 
blocker for ≥9 months; had no biologics 6 months before index TNF treatment; and 
reported a Health Assessment Questionnaire Disability Index (HAQ-DI) at index and 
9–15 months after index. Self-reported dosing information was validated by telephone 
follow-up, medical, billing, or retail pharmacy prescription records. Dose escalation 
was deﬁ ned as dosing above ﬁ rst ADA/ETN or third INF dose. Multivariate models 
compared HAQ-DI change and dose escalation rates, controlling for variables that 
differed among INF, ADA and ETN patients at index. RESULTS: Approximately 351 
patients (93 INF, 40 ADA, 218 ETN) met study criteria. Subjects were mostly female 
(83%), Caucasian (88%), and had mean disease duration of 18.9 years. HAQ-DI 
change scores at 9–15 months did not differ by treatment (−0.10, −0.08, and −0.12 
points for INF, ADA, and ETN, respectively; P = 0.52). Dose increases were observed 
in 1.4% of ETN patients, as compared with 10.8% of INF (P < 0.001) and 12.5% 
of ADA patients (P = 0.004, both vs. ETN). HAQ-DI change was associated with 
pre-index HAQ-DI score and disease duration (both P < 0.05). CONCLUSIONS: This 
study showed dose escalation in fewer ETN than INF or ADA patients, but similar 
improvements in functional disability.
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IMPROVEMENT IN EFFICACY AND SAFETY OUTCOMES AFTER 
CERVICAL ARTHROPLASTY VERSUS STANDARD ANTERIOR CERVICAL 
DISECTOMY AND FUSION (ACDF) SURGERIES: A META-ANALYSIS OF 
PUBLISHED RCTS
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BACKGROUND: Cervical arthroplasty has been used successfully worldwide for over 
a decade in patients with cervical degenerative disc disease (CDDD). Several RCTs have 
documented the clinical advantage of arthroplasty vs. fusion for this patient population. 
Synthesis of outcomes from published RCTs is needed to consolidate the evidence-base 
for arthroplasty in CDDD. OBJECTIVES: To examine current evidence of safety and 
efﬁ cacy in the use of arthroplasty to treat CDDD and conduct a pooled analysis of high 
level comparative outcomes for arthroplasty versus fusion. METHODS: A systematic 
search of the PubMed, EMBASE, MEDLINE, CRD York, and Cochrane Library data-
bases, plus hand searching of grey literature was undertaken in January 2010. RESULTS: 
A total of 554 non-duplicate citations were retrieved. Only three studies of arthroplasty 
versus fusion with 2 years follow-up met all inclusion criteria and were of reasonable 
quality (according to GRADE criteria) to pool. a meta-analysis was conducted using 
RevMan5 software (Cochrane 2008). Persons undergoing single-level arthroplasty had 
signiﬁ cantly improved neurological success (RR 1.14, 95% CI [1.07, 1.21] P < 0.0001), 
Neck Disability Index (NDI) success (RR 1.13, 95% CI [1.05, 1.22] P = 0.001) and 
overall success (RR 1.22 95% CI [1.12, 1.33], P < 0.00001) at 2 years post surgery 
compared to fusion. Secondary surgeries (any revision, removal, or re-operation of the 
implant or supplemental ﬁ xation) after 2 years were also signiﬁ cantly lower with 
arthroplasty (13/621) compared to fusion (39/592), [0.32 95% CI [0.17, 0.59) P = 
0.0003]. Total number of patients undergoing reoperations at adjacent levels was lower 
in arthroplasty-treated patients (9/621) vs. ACDF (17/592), however it was not statisti-
cally signiﬁ cant (P = 0.09). Given the small numbers of patients undergoing reoperations 
at adjacent levels, longer term results are needed to increase precision of this estimate. 
CONCLUSIONS: A formal pooled analysis of 2-year RCT data demonstrates clinically 
signiﬁ cant improvements in efﬁ cacy and safety outcomes in CDDD patients who have 
undergone arthroplasty versus standard fusion.
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OBJECTIVES: To determine in patients with RA the number needed to treat (NNT) 
to achieve minimum clinically important differences (MCIDs) in multiple patient 
